BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8854672)

  • 21. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy.
    Chokephaibulkit K; Wanachiwanawin D; Chearskul S; Wanprapa N; Unganont K; Tantinikorn W; Udompunthurak S
    Pediatr Infect Dis J; 1999 Feb; 18(2):147-52. PubMed ID: 10048687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The first one hundred AIDS cases in Hong Kong.
    Lee SS; Lo YC; Wong KH
    Chin Med J (Engl); 1996 Jan; 109(1):70-6. PubMed ID: 8758375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium.
    Maldonado YA; Araneta RG; Hersh AL
    Pediatr Infect Dis J; 1998 May; 17(5):398-402. PubMed ID: 9613653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia.
    Gallant JE; McAvinue SM; Moore RD; Bartlett JG; Stanton DL; Chaisson RE
    Chest; 1995 Apr; 107(4):1018-23. PubMed ID: 7705108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of Pneumocystis carinii pneumonia: who are we missing?
    Schwarcz SK; Katz MH; Hirozawa A; Gurley J; Lemp GF
    AIDS; 1997 Aug; 11(10):1263-8. PubMed ID: 9256945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severity and outcome of Pneumocystis carinii pneumonia (PCP) in patients of known and unknown HIV status.
    Mallal SA; Martinez OP; French MA; James IR; Dawkins RL
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):148-53. PubMed ID: 7905524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
    Hardy WD; Feinberg J; Finkelstein DM; Power ME; He W; Kaczka C; Frame PT; Holmes M; Waskin H; Fass RJ
    N Engl J Med; 1992 Dec; 327(26):1842-8. PubMed ID: 1448121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.
    Kazanjian P; Locke AB; Hossler PA; Lane BR; Bartlett MS; Smith JW; Cannon M; Meshnick SR
    AIDS; 1998 May; 12(8):873-8. PubMed ID: 9631140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
    Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL;
    AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus.
    Zar HJ; Dechaboon A; Hanslo D; Apolles P; Magnus KG; Hussey G
    Pediatr Infect Dis J; 2000 Jul; 19(7):603-7. PubMed ID: 10917216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumocystis carinii infections in HIV-infected hemophiliacs during aerosolized pentamidine prophylaxis.
    Ewig S; Rockstroh JK; Seitz HM; Marklein G; Christ F; Lüchters G; Brackmann HH; Lüderitz B
    Respiration; 1993; 60(3):186-92. PubMed ID: 8210724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982-1993 [corrected].
    Klatt EC; Nichols L; Noguchi TT
    Arch Pathol Lab Med; 1994 Sep; 118(9):884-90. PubMed ID: 8080357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical manifestations and survival trends during the first 12 years of the AIDS epidemic in Mexico.
    Villasís-Keever A; Rangel-Frausto MS; Ruiz-Palacios G; Ponce de León-Rosales S
    Arch Med Res; 2001; 32(1):62-5. PubMed ID: 11282182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of antiretroviral treatment and prophylaxis for opportunistic infections on survival of patients with AIDS].
    Gálvez Hermoso C; Blanco Quintana F; del Amo Valero J; Díez Ruiz-Navarro M; Soriano Vázquez V; González Lahoz J
    Rev Clin Esp; 2000 Apr; 200(4):187-92. PubMed ID: 10857401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group.
    Easterbrook PJ; Keruly JC; Creagh-Kirk T; Richman DD; Chaisson RE; Moore RD
    JAMA; 1991 Nov; 266(19):2713-8. PubMed ID: 1942423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.